Home/Filings/4/0001209191-18-056072

4//SEC Filing

NEW ENTERPRISE ASSOCIATES 13 LP 4

Accession 0001209191-18-056072

CIK 0001169245other

View on SEC.gov Company Profile

Filed

Oct 23, 8:00 PM ET

Accepted

Oct 24, 5:01 PM ET

Size

40.2 KB

Accession

0001209191-18-056072

Insider Transaction Report

Form 4

Period: 2018-10-22

PhaseBio Pharmaceuticals IncPHAS

NEA 13 GP, Ltd

10% Owner

Transactions

Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)

NEW ENTERPRISE ASSOCIATES 13 LP

10% Owner

Transactions

Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)

NEA Partners 13, Limited Partnership

10% Owner

Transactions

Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)
Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)

KERINS PATRICK J

10% Owner

Transactions

Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)

Viswanathan Ravi

10% Owner

Transactions

Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)

BARRETT M JAMES

10% Owner

Transactions

Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)

BARRIS PETER J

10% Owner

Transactions

Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)

BASKETT FOREST

10% Owner

Transactions

Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)

MOTT DAVID M

10% Owner

Transactions

Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)

SANDELL SCOTT D

10% Owner

Transactions

Conversion
Common Stock
2018-10-22+4,841,634→ 4,841,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−181,190→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series C-1 Preferred Stock (181,190 underlying)
Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+181,190$21,743→ 442,055 total(indirect: See Note 2)
→ Common Stock (181,190 underlying)
Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−4,349$21,745→ 437,706 total(indirect: See Note 2)
→ Common Stock (4,349 underlying)
Conversion
Series C-1 Preferred Stock
2018-10-22−437,706→ 0 total(indirect: See Note 2)
→ Common Stock (437,706 underlying)
Purchase
Common Stock
2018-10-22$5.00/sh+1,800,000$9,000,000→ 6,641,634 total(indirect: See Note 2)
Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−49,030→ 0 total(indirect: See Note 2)
Exercise: $0.12→ Series B Preferred Stock (49,030 underlying)
Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+49,030$5,884→ 3,280,804 total(indirect: See Note 2)
→ Common Stock (49,030 underlying)
Sale
Series B Preferred Stock
2018-10-22$5.00/sh−1,177$5,885→ 3,279,627 total(indirect: See Note 2)
→ Common Stock (1,177 underlying)
Conversion
Series B Preferred Stock
2018-10-22−3,279,627→ 0 total(indirect: See Note 2)
→ Common Stock (3,279,627 underlying)
Conversion
Series D Preferred Stock
2018-10-22−1,124,301→ 0 total(indirect: See Note 2)
→ Common Stock (1,124,301 underlying)

Footnotes (4)

[F1]Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
[F2]The securities are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and each of the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 13 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Patrick J. Kerins, David M. Mott, Scott D. Sandell and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 securities in which the Indirect Reporting Persons have no pecuniary interest.
[F3]Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
[F4]The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

PhaseBio Pharmaceuticals Inc

CIK 0001169245

→

Entity typeother

IncorporatedCayman Islands

Related Parties

filerCIK 0001452907

Filing Metadata

Form type: 4
Filed: Oct 23, 8:00 PM ET
Accepted: Oct 24, 5:01 PM ET
Size: 40.2 KB

View on SEC.gov